NASDAQ:KITE
Delisted

Kite Pharma Fund News

etoro logo Buy KITE
*Your capital is at risk
$179.79
+0 (+0%)
At Close: Oct 19, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it will report second quarter 2017 financial results on Tuesday, August 8,
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report first quarter 2017 financial results on Monday, May 8, 2017 prior to the open of U.S. based
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2016 financial results on Tuesday, February 28, 2017, prior to t
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report third quarter 2016 financial results on Wednesday, November 9, 2016, prior to the open of the
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced positive topline results from a pre-planned interim analysis of ZUMA-1 for its lead product candidate, KTE-C19,
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will report second quarter 2016 financial results on Monday, August 8, 2016, after market close. The anno
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report first quarter 2016 financial results on Monday, May 9, 2016 after market close. The announce
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE